|Bid||50.00 x 1000|
|Ask||75.00 x 800|
|Day's Range||61.99 - 65.32|
|52 Week Range||19.68 - 92.77|
|Beta (5Y Monthly)||2.07|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -26.92% and -70.27%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Arvinas (NASDAQ:ARVN) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share decreased 76.79% year over year to ($0.99), which missed the estimate of ($0.78). Revenue of $2,218,000 decreased by 54.67% year over year, which missed the estimate of $6,910,000. Outlook Earnings guidance hasn't been issued by the company for now. View more earnings on ARVN Arvinas hasn't issued any revenue guidance for the time being. Recent Stock Performance 52-week high: $92.77 52-week low: $19.68 Price action over last quarter: Up 256.56% Company Profile Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. See more from BenzingaClick here for options trades from BenzingaRecap: Biohaven Pharmaceutical Q4 EarningsSuperior Group: Q4 Earnings Insights© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.